Advanced Oncotherapy (AVO) – Exercise of Warrants, Issue of Shares and Holdings in Company

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 2,000,000 new ordinary shares (“New Shares”) of 25 pence in the Company to PI-Capital LLC, pursuant to the exercise of 2,000,000 warrants at 27.5 pence per New Share.  The warrants were issued in 2012.  

Following the issue of New Shares, PI-Capital LLC holds 2,000,000 Ordinary Shares representing 3.4% of the issued share capital of the Company.

Application has been made for the 2,000,000 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 01 August 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.

Total voting rights

Following Admission, the Company’s enlarged issued share capital will comprise 58,780,361 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 58,780,361. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.

For further information, please contact: